



April 2008


C.L. Bergman, CEO

+31 (0) 320 26 77 99


ir@fornix.nl

- Overview of Fornix
- Strategy
- Financials
- Update Oralgen® registration process
- Q&A

Company Overview



Snapshot of Fornix by the end of 2007 (1)



(1) Results based on provisional annual results

(2) Currently being divested

Products per Division

ALLERGY DIVISION

Immunotherapy

- Oralgen®: sublingual
- Pollinex®: subcutaneous
- Artuvetrin®: veterinary

Emergency rescue medication

- Anapen®

Diagnostic

- Skin prick tests
- Artuvetrin® SerumTest

Lactose intolerance

- Kerutabs® / Kerulac®

MEDICAL DEVICES DIVISION

Activities focused on selected product groups:

- Urology
- Stomacare
- Woundcare
- Gynaecology
- Incontinency
- Decubites
- Hygiene
- Hip protector Safehip®
- Wound/Scar treatment – Scarban®

Fornix' Acquisition Strategy



FORNIX' STRATEGY

- Fornix aims to achieve prominent positions in the niches in which it operates
- Fornix views the Netherlands as its domestic market. However, Fornix is also increasingly active in other EU countries
- In addition, the company is striving to diversify its operations and would become active in other medical sectors in order to mitigate risk

FORNIX' ACQUISITION CRITERIA

- Requirements of a potential target:
 - Active in Healthcare
 - Strong competitive position
 - Profitable, cash flow generating business
 - Viable future business case
 - Active in growing segment(s)
 - Strong and experienced management
 - Potential for further organic and acquisitive growth
 - International potential

Strategy by Division

- **Fornix aims to achieve prominent positions in its niche markets**

ALLERGY DIVISION

- Remain Dutch market leader in Allergy
- Investment in Clinical Development Plan will result in definitive registration of Oralgen® products
- Oralgen® roll out in Europe
- Netherlands: utilising sales force of approx. 50 persons
- Further growth both autonomous and through acquisitions

MEDICAL DEVICES DIVISION


- Accomplish strong growth of activities by:
 - Acquisitions in medical devices markets in NL en EU
 - Autonomous growth of current activities; expansion of activities in EU
- Retain its position as a supplier of specialised products
- Discontinue less profitable products

Financial Overview Fornix BioSciences



KEY PERFORMANCE SINCE 2002 (€ MILLION)

COMMENTS



- Turnover increase by strong performance of Oralgene® and (since 2006) the Medical Devices division;

Trading division divested per 1.10.2007

- Increase in margins driven by Allergy and Medical Devices
- Estimates for 2008:
 - Turnover € 41 mln (+8%)
 - Net Profit € 11,8 mln (0%)

Share Price Overview & Market Data



8 YEAR SHARE PRICE PERFORMANCE FORNIX vs. ASCX INDEX

MARKET DATA per 1 January 2008

Koersontwikkeling Fornix Biosciences



— Midkap-index
— Fornix share price

	€	%
Share price:	€ 18,80	100%
52- week High:	€ 23,90	127%
52-week Low:	€ 15,15	81%
Shares outstanding ¹ :	7.262.170 Million	
Market Cap (€M):	136,5	

(1) Adjusted for outstanding options and treasury stock

Update on Oralgen Registration Process

- Appeal against previous rejection of application for registration of Oralgen® Pollen declared unfounded by Dutch Medicines Evaluation Board (CBG)
- Results of current Oralgen® Grass Pollen study crucially important to application for definitive registration of Oralgen® Pollen; provisional registration remains in force
- Good progress in recruiting patients for Oralgen® Grass Pollen study now in progress
- Current Oralgen® Grass Pollen study to be completed by end of 2007 and initial findings to be announced in early 2008
- New Oralgen® Mites parallel study under consideration

Q&A